STOCK TITAN

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences

OS Therapies (NYSE-A: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, has announced its participation in The Jones Healthcare and Technology Innovation Conference. The event will take place on April 8-9, 2025 at the Venetian Resort in Las Vegas.

CEO Paul Romness and CBO Gerald Commissiong will be available for meetings with registered investors during the conference. The event, hosted by JonesTrading Institutional Services, , aims to connect leading healthcare and technology companies with institutional investors and opinion leaders.

The conference will feature:

  • Expert-led panels
  • Corporate presentations
  • Fireside chats
  • One-on-one meetings
focusing on the latest trends and innovations in healthcare and technology sectors.

OS Therapies (NYSE-A: OSTX), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapia e Antibody Drug Conjugate (ADC), ha annunciato la sua partecipazione alla Jones Healthcare and Technology Innovation Conference. L'evento si svolgerà il 8-9 aprile 2025 presso il Venetian Resort di Las Vegas.

Il CEO Paul Romness e il CBO Gerald Commissiong saranno disponibili per incontri con gli investitori registrati durante la conferenza. L'evento, ospitato da JonesTrading Institutional Services, ha l'obiettivo di connettere le principali aziende del settore sanitario e tecnologico con investitori istituzionali e leader di opinione.

La conferenza presenterà:

  • Pannelli guidati da esperti
  • Presentazioni aziendali
  • Conversazioni informali
  • Incontri individuali
che si concentreranno sulle ultime tendenze e innovazioni nei settori della salute e della tecnologia.

OS Therapies (NYSE-A: OSTX), una compañía biofarmacéutica en etapa clínica especializada en inmunoterapia y Antibody Drug Conjugate (ADC), ha anunciado su participación en la Jones Healthcare and Technology Innovation Conference. El evento se llevará a cabo el 8-9 de abril de 2025 en el Venetian Resort en Las Vegas.

El CEO Paul Romness y el CBO Gerald Commissiong estarán disponibles para reuniones con inversores registrados durante la conferencia. El evento, organizado por JonesTrading Institutional Services, tiene como objetivo conectar a las principales empresas de salud y tecnología con inversores institucionales y líderes de opinión.

La conferencia contará con:

  • Paneles dirigidos por expertos
  • Presentaciones corporativas
  • Charlas informales
  • Reuniones uno a uno
que se centrarán en las últimas tendencias e innovaciones en los sectores de salud y tecnología.

OS Therapies (NYSE-A: OSTX), 임상 단계의 면역 요법 및 항체 약물 접합체(ADC) 생명공학 회사가 Jones Healthcare and Technology Innovation Conference에 참여한다고 발표했습니다. 이 행사는 2025년 4월 8-9일 라스베가스의 Venetian Resort에서 개최됩니다.

CEO Paul Romness와 CBO Gerald Commissiong는 회의 중 등록된 투자자와의 미팅을 위해 대기할 것입니다. JonesTrading Institutional Services가 주최하는 이 행사는 주요 헬스케어 및 기술 기업과 기관 투자자 및 의견 리더를 연결하는 것을 목표로 합니다.

이번 컨퍼런스에서는:

  • 전문가 주도의 패널
  • 기업 발표
  • 파이어사이드 챗
  • 1:1 미팅
헬스케어 및 기술 분야의 최신 동향과 혁신에 초점을 맞출 것입니다.

OS Therapies (NYSE-A: OSTX), une entreprise biopharmaceutique en phase clinique spécialisée dans l'immunothérapie et le conjugé de médicaments anticorps (ADC), a annoncé sa participation à la Jones Healthcare and Technology Innovation Conference. L'événement se déroulera les 8-9 avril 2025 au Venetian Resort à Las Vegas.

Le PDG Paul Romness et le CBO Gerald Commissiong seront disponibles pour des réunions avec les investisseurs enregistrés pendant la conférence. L'événement, organisé par JonesTrading Institutional Services, vise à connecter les principales entreprises de santé et de technologie avec des investisseurs institutionnels et des leaders d'opinion.

La conférence comprendra:

  • Panneaux dirigés par des experts
  • Présentations d'entreprises
  • Discussions informelles
  • Réunions individuelles
axées sur les dernières tendances et innovations dans les secteurs de la santé et de la technologie.

OS Therapies (NYSE-A: OSTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immuntherapie und Antibody Drug Conjugate (ADC) spezialisiert hat, hat seine Teilnahme an der Jones Healthcare and Technology Innovation Conference angekündigt. Die Veranstaltung findet am 8.-9. April 2025 im Venetian Resort in Las Vegas statt.

CEO Paul Romness und CBO Gerald Commissiong stehen während der Konferenz für Meetings mit registrierten Investoren zur Verfügung. Die von JonesTrading Institutional Services ausgerichtete Veranstaltung zielt darauf ab, führende Unternehmen im Gesundheits- und Technologiebereich mit institutionellen Investoren und Meinungsführern zu verbinden.

Die Konferenz wird Folgendes umfassen:

  • Expertengeführte Panels
  • Unternehmenspräsentationen
  • Fireside Chats
  • Einzelgespräche
, die sich auf die neuesten Trends und Innovationen in den Bereichen Gesundheit und Technologie konzentrieren.

Positive
  • None.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company’s participation aligns with its prioritization of advancements in healthcare and technology while connecting with other investors.

Event: Jones Healthcare and Technology Innovation Conference

Date: April 8-9, 2025

The conference is hosted by JonesTrading Institutional Services, LLC, a leading full-service investment banking firm providing a comprehensive suite of services, including capital markets, M&A, and strategic advisory to corporate clients. The event aims to bring together leading healthcare and technology companies, institutional investors, and opinion leaders to explore the latest trends and innovations shaping both industries. The conference will offer expert-led panels, corporate presentations, fireside chats, and one-on-one meetings covering advancements in healthcare and technology.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled "Risk Factors" of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the "SEC") on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate and Media Contact:

Jack Doll

410-297-7793

Irpr@ostherapies.com

Source: OS Therapies

FAQ

When and where will OS Therapies (OSTX) attend the Jones Healthcare Conference?

OS Therapies will attend the Jones Healthcare and Technology Innovation Conference on April 8-9, 2025, at the Venetian Resort in Las Vegas.

Which OS Therapies (OSTX) executives will be present at the Jones Healthcare Conference 2025?

CEO Paul Romness and CBO Gerald Commissiong will be attending and accepting meetings with registered investors.

What type of activities will be featured at the 2025 Jones Healthcare Conference where OSTX is participating?

The conference will include expert-led panels, corporate presentations, fireside chats, and one-on-one meetings focused on healthcare and technology innovations.

What is OS Therapies' (OSTX) current business focus in the healthcare sector?

OS Therapies is a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company.
OS THERAPIES INCORPORATED

NYSE:OSTX

OSTX Rankings

OSTX Latest News

OSTX Stock Data

31.78M
14.41M
34.84%
0.67%
2.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE